Immunophenotyping
Flow cytometry experiments were conducted to explore changes in the immune microenvironment upon treatment. Data from Parts A and B were obtained from peripheral blood collected at Day 1 of Cycle 1 (27 and 43 patients, respectively), Day 1 of Cycle 3 (20 and 38 patients), and end of treatment (8 and 9 patients) for the all-treated population.For the all-treated population, at Day 1 of Cycle 3 compared with baseline, the percentages of CD19 + B cells (2.33% to 0.66%), CD4 + T cells (15.56% to 11.27%), CD3 + T cells (23.56% to 19.00%), NK cells (CD56As all patients except 1 responded to the treatment, no correlation with parameters of clinical response was performed.